Predictive Oncology Inc. (POAI): Utang-utang marang kapitalisasi buku

Tandha merek predictive-oncology.com (POAI)

Driven by demand for AI-driven pharma and FDA support, Predictive Oncology (POAI) retains partners through cell-based test simulations. Its proprietary bioinformatics environment creates a network effect powered by a database of tumor reactions. Historical debt-to-book value dynamics confirm financial stability, where 0.00 captures the current state of the parameter. Revenue is based on analytics licensing and conducting research for the development of personalized cancer treatments.

POAI (Predictive Oncology Inc.) riwayat Utang marang nilai buku saka 04.07.2022 nganti 12.12.2025

Ringkesan rincian data analitis predictive-oncology.com (POAI)

- rega lan prakiraan konsensus rega:
Rega saham Predictive Oncology Inc.|POAI - Prakiraan gabungan firma investasi
- data kapitalisasi pasar:
Kapitalisasi pasar POAI|POAI - Rega Tumbas Perusahaan
- data kapitalisasi buku:
Nilai Buku saben Saham Predictive Oncology|POAI - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku predictive-oncology.com|POAI - Total Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Predictive Oncology|POAI - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Predictive Oncology Inc.|POAI - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku POAI
Analisis fundamental perusahaan:Predictive Oncology Corp
Produk asli Predictive Oncology Inc

Predictive Oncology monetizes its AI platform through B2B subscriptions to optimize the development of anti-tumor drugs. This indicator compares total liabilities to the book value of equity to determine the degree of financial leverage. Analyzing the value of debt relative to book capitalization allows for an assessment of insolvency risk under high debt loads. A declining curve confirms increasing business autonomy and resilience to external shocks. Conservative investors interpret a low ratio as a guarantee of the issuer's solvency.

Karo sapa Predictive Oncology saingan

ISRG - Utang-utang marang kapitalisasi buku|Rasio utang marang nilai buku danaher.com DHR|Utang-utang marang kapitalisasi buku BDX (Becton Dickinson)|STE - Utang-utang marang aset resik|WST (West Pharmaceutical Services Inc) - Utang-utang marang kapitalisasi buku|Baxter Healthcare (BAX) - Utang marang nilai buku|MASI (Masimo Corporation) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku STVN|Rasio utang marang kapitalisasi buku Teleflex (TFX)|Rasio utang marang kapitalisasi buku Merit Medical Systems, Inc. MMSI|Utang marang nilai buku Envista Holdings Corp|Rasio utang marang aset resik ICU Medical Inc. ICUI|Utang-utang marang kapitalisasi buku XRAY (DENTSPLY SIRONA Inc.)|LMAT: Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku AtriCure|STAA (STAAR Surgical Co.) - Rasio utang marang nilai buku|NAGE: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik ZimVie Corp (ZIMV)|Utang marang nilai buku AngioDynamics, Inc.|Utang marang modal buku CERS (cerus.com)|Rasio utang marang kapitalisasi buku Teknova|MGRM - Rasio utang marang aset resik|Sharps Tech - Utang marang nilai buku|INFU: Utang-utang marang kapitalisasi buku|UTMD (Utah Medical Products) - Rasio utang marang kapitalisasi buku|KORU Medical (KRMD) - Utang marang nilai buku|Utang-utang marang kapitalisasi buku NYXH (Nyxoah)|Utang-utang marang nilai buku MBOT|Rasio utang marang kapitalisasi buku Pro-Dex Corp PDEX|Rasio utang marang nilai buku Zentek Corp ZTEK|Utang marang nilai buku Elutia Inc. (ELUT)|milestonescientific.com - Utang marang modal buku|Rasio utang marang kapitalisasi buku NXGL (NEXGEL)|RVP: Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku Harvard Bioscience, Inc. (HBIO)|FEMY (Femasys Corporation) - Rasio utang-utang marang kapitalisasi buku|MHUA - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik Callan JMB Corp|Atrion - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku NeuroMetrix Inc (NURO)